araag2/HINT huggingface dataset:
Clinical trial NCT00320710 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: zoledronic acid, placebo
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Female patients ≥ 18 years of age. Confirmed breast cancer with bone metastasis. Pretreated
        with Zometa®, or Aredia (pamidronate) or all sequential regimens of both, for a minimum of
        9 doses;

        Exclusion Criteria:

        Abnormal kidney function determined by serum creatinine levels. Current active dental
        problems including: ongoing infection of the teeth or jawbone; current exposed bone in the
        mouth; and current or prior diagnosis of osteonecrosis of the jaw.

        Recent (within 8 weeks) or planned dental or jaw surgery (e.g., extraction, implants).

        Diagnosis of metabolic bone disease other than osteoporosis (e.g., Paget's disease of
        bone).

        Known hypersensitivity to Zometa. Treatment with other investigational drugs within 30 days
        prior to randomization.

        Other protocol-defined exclusion criteria may have applied.
Clinical trial NCT01559116 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: tiotropium + olodaterol, tiotropium, olodaterol, tiotropium, tiotropium + olodaterol, placebo
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          1. Diagnosis of chronic obstructive pulmonary disease

          2. Relatively stable airway obstruction with a post-bronchodilator FEV1< 80% of predicted
             normal and a post-bronchodilator FEV1/FVC <70%

          3. Male or female patients, 40 years of age or older

          4. Smoking history of more than 10 pack years

          5. Ability to perform technically acceptable pulmonary function tests and maintain
             records

          6. Ability to inhale medication in a competent manner from the RESPIMAT Inhaler and from
             a metered dose inhaler (MDI)

        Exclusion criteria:

          1. significant disease other than COPD

          2. clinically relevant abnormal lab values

          3. history of asthma

          4. diagnosis of thyrotoxicosis

          5. diagnosis of paroxysmal tachycardia

          6. history of myocardial infarction

          7. unstable or life-threatening cardiac arrhythmia

          8. Hospitalization for heart failure within the past year

          9. known active tuberculosis

         10. malignancy for which patient has undergone resection, radiation therapy or
             chemotherapy within last five years

         11. history of life-threatening pulmonary obstruction

         12. history of cystic fibrosis

         13. clinically evident bronchiectasis

         14. history of significant alcohol or drug abuse

         15. history of thoracotomy with pulmonary resection

         16. oral or patch ß-adrenergics

         17. oral corticosteroid medication at unstable doses

         18. regular use daytime oxygen therapy for more than one hour per day

         19. Pulmonary rehabilitation program in the six weeks prior to the screening visit

         20. Investigational drug within one month or six half lives (whichever is greater) prior
             to screening visit

         21. Known hypersensitivity to ß-adrenergic drugs, BAC, EDTA

         22. Pregnant or nursing women

         23. Women of childbearing potential not using a highly effective method of birth control

         24. Patients who have previously been randomised in this study or are currently
             participating in another study

         25. Patients who are unable to comply with pulmonary medication restrictions prior to
             randomisation
Clinical trial NCT01402024 (phase 3, status: completed)
Conditions: chemotherapy induced nausea and vomiting
ICD codes: D61.810, Z51.11, D64.81, D70.1, Z92.21, P04.11, T80.810S
Drugs: aprepitant, placebo
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  All subjects must have a confirmed diagnosis of malignancy and receiving highly
             emetogenic chemotherapy first time (VAC, ABVD and CDDP/Doxorubicin)

          -  Age group 5-18 years with weight between 15-65 kg

          -  Children/adolescents and their caregiver who can understand Hindi or English and
             willing to participate in the study (with written informed consent)

        Exclusion Criteria:

          -  Significant organ dysfunction

          -  Active infection

          -  Pregnancy

          -  Uncontrolled medical condition other than malignancy

          -  Need for contraindicated concomitant medication

          -  Patients receiving chemotherapy other than VAC, ABVD and CDDP/Doxorubicin

          -  Treatment with another investigational drug within 4 weeks of study start or prior
             Aprepitant use

          -  Had received or will receive RT to abdomen or pelvis in the week prior to treatment

          -  Vomited in the 24 hr prior to treatment

          -  Prior exposure to highly emetogenic chemotherapeutics

          -  Abnormal lab values (ANC<1500/mm3, TLC<3000/mm3, Plt<100,000/mm3, AST/ALT> 2.5 times
             of ULN, bill>1.5 times of ULN, S.cr>1.5 times of ULN, patient on systemic steroids
Clinical trial NCT00452270 (phase 3, status: completed)
Conditions: common cold
ICD codes: J00, T48.5X6S, T48.5X3S, T48.5X4S, T48.5X5S, T48.5X6A, T48.5X6D
Drugs: xylometazoline
SMILES: CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Over 18 years

          -  Have had moderate common cold symptoms for less than 36 hours.

        Exclusion Criteria:

          -  Congested/runny nose for more than two continuous weeks in the previous 12 months

          -  Deviated septum or nasal polyps

          -  Recent use of antibiotics

          -  Recent sinusitis

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT01186770 (phase 3, status: completed)
Conditions: opioid-induced constipation
ICD codes: F11.14, F11.181, F11.182, F11.188, F11.19, F11.24, F11.281
Drugs: methylnaltrexone, placebo
SMILES: C[N@+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          1. History of chronic non-malignant pain (originating from a non-malignant source) with
             condition(s) underlying the chronic pain of greater than or equal to (≥) 2 months'
             duration before the screening visit.

          2. Taking oral, transdermal, intravenous (IV), or subcutaneous (SC) opioids for chronic
             non-malignant pain for ≥1 month.

          3. No known history of chronic constipation prior to the initiation of opioid therapy.

          4. Currently taking laxative therapy for ≥30 days and willing to discontinue all laxative
             therapy at the start of screening period and use only study-permitted rescue laxatives
             throughout the screening and double-blind treatment periods..

        Key Exclusion Criteria:

          1. Prior treatment with oral MNTX.

          2. Prior treatment with SC MNTX within 30 days of screening.

          3. Women who are pregnant, breastfeeding, or plan to become pregnant during the study.

          4. Fecal incontinence, rectal prolapse, fecal ostomy or other clinically significant
             gastrointestinal disorders such as inflammatory bowel disease or clinically
             significant irritable bowel syndrome that would have made bowel movement assessment
             inaccurate.

          5. Current treatment with partial opioid agonists (for example; buprenorphine) or
             combination agonists/antagonists.
Clinical trial NCT00424606 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel, epirubicin, epirubicin, docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed breast adenocarcinoma.

          -  Within 20-45 days after the surgical excision of the primary tumor with tumor-free
             operation margins; at least 10 axillary lymph nodes have to be removed.

          -  Absence of lymph node involvement after eclosion and hormone (E&H) staining and light
             microscopy evaluation.

          -  Premenopausal or postmenopausal women with at least one of the following tumor
             characteristics is required in order to characterize the tumor as high risk:

               -  Estrogen receptor (ER) (-) and progesterone receptor (PR)(-);

               -  Ki-67 + > 30%; Grade III; HER2 (3+) (after an amendment on 15.05.2008 women with
                  HER2 (3+) were not included); Perineural infiltration or presence of tumor emboli
                  in blood or lymph vessels.

          -  Postmenopausal women with tumors 1-2 cm are eligible if the tumor has at least 2 of
             the above mentioned high risk criteria.

          -  Premenopausal and postmenopausal women with tumors measuring > 2 cm are eligible
             irrespectively of the expression of the above adverse prognostic tumor criteria.

          -  Absence of any clinical or radiological evidence of local or metastatic disease.

          -  Age > 18 years.

          -  Performance status (WHO) < 3.

          -  Adequate bone marrow function (absolute neutrophil count > 1000/mm^3, platelet count >
             100000/mm^3, hemoglobin > 9 gr/mm^3).

          -  Adequate liver (bilirubin < 1.5 times upper limit of normal and SGOT/SGPT < 2 times
             upper limit of normal) and renal function (creatinine < 2 mg/dl).

          -  Adequate cardiac function (LVEF > 50%).

          -  Negative pregnancy test.

          -  Informed consent.

        Exclusion Criteria:

          -  Other invasive malignancy within the past 5 years except nonmelanoma skin cancer.

          -  Other concurrent uncontrolled illness that could affect compliance with the study.

          -  Psychiatric illness or social situation that would preclude study compliance.

          -  Pregnant or nursing women.

          -  History of allergic reaction attributed to docetaxel.

          -  Other concurrent investigational agents.
Clinical trial NCT01235442 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: 1=etanercept, 2=clobetasol propionate foam
SMILES: [H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has had stable moderate to severe plaque psoriasis for at least 6 months

          -  Subject has involved BSA ≥ 10% and PASI ≥ 10 at screening and at baseline.

          -  Subject is a candidate for systemic therapy or phototherapy in the opinion of the
             investigator

        Exclusion Criteria:

          -  Subject has active guttate, erythrodermic, or pustular psoriasis at the time of the
             screening visit.

          -  Subject has evidence of skin conditions at the time of the screening visit (eg,
             eczema) that would interfere with evaluations of the effect of etanercept
             and/orclobetasol propionate foam on psoriasis.

          -  Subject diagnosed with medication-induced or medication exacerbated psoriasis

          -  Subject has any active Common Toxicity Criteria (CTC) grade 2 or higher infection

          -  Subject has a significant concurrent medical condition or laboratory abnormalities as
             defined in the study protocol.

          -  Subject has used any of the following therapies within 14 days of the first dose: UVB
             therapy or topical psoriasis therapies other than Class I or II topical steroids.

          -  Subject has used any of the following therapies within 28 days of the first dose:
             Class I or II topical steriods, UVA therapy (with or without psoralen), or systemic
             psoriasis therapies

          -  Subject has used one or more biologic therapies (other than interleukin (IL)12/IL23
             inhibitors) within 3 months of the first dose

          -  Subject has used an IL-12/IL-23 inhibitor within 6 months of the first dose of
             etanercept

          -  Subject has ever used efalizumab (Raptiva®).
Clinical trial NCT01560091 (phase 3, status: withdrawn)
Conditions: kidney stones
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: silodosin, tamsulosin
SMILES: C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F, CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O
Reason stopped: 
    accrual of subjects did not occur as anticipated
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adults age 18 to 70

          -  Non-diabetics

          -  White blood cell count and serum creatinine level within normal range

          -  Urine analysis consistent with absence of infection

          -  Negative urine culture

          -  Absence of subjective or objective fever

          -  Ability to tolerate oral fluids and pain medication

          -  Unilateral ureteral calculus < 10mm visible on CT scan within the ureter

          -  Ability to make informed medical decisions regarding consent

          -  Willingness to follow up in the urology office

        Exclusion criteria:

        Adults unable to consent

          -  Individuals who are not yet adults (infants, children, teenagers)

          -  Pregnant women

          -  Prisoners

          -  Prior treatment for this particular stone

          -  Medical therapy only for stone disease

          -  Chronic narcotic use

          -  Current alpha blocker therapy
Clinical trial NCT01418651 (phase 3, status: terminated)
Conditions: fibromyalgia
ICD codes: M79.7
Drugs: savella
SMILES: CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1
Reason stopped: 
    lack of subjects
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients.

          -  Age 65 years or older.

          -  Fibromyalgia diagnosed according to ACR 1990 criteria.

          -  Pain Score ≥ 10 on Gracely scale at screening and baseline assessments.

          -  Discontinuation of other dual-acting antidepressant medications, including duloxetine,
             venlafaxine, and tricyclic antidepressants for a period not less than 4.5 times the
             drug half-life as of the baseline evaluation.

        Exclusion Criteria:

          -  Uncontrolled hypertension (BP ≥ 140/90) at screening or baseline evaluations.

          -  Baseline orthostasis (documented drop in SBP ≥ 20 mmHg or in DBP ≥ 10 mmHg within 3
             minutes after standing) at screening or baseline evaluations.

          -  Psychosis, active suicidality, current episode of major depression or other severe
             psychiatric illness, or current alcohol/substance abuse or dependence as assessed by
             the MINI.

          -  Significant cardiovascular disease, including atrial fibrillation or other
             dysrhythmia, congestive heart failure, valvular heart disease, or QTc prolongation on
             baseline EKG (> 450 msec).

          -  Uncontrolled narrow angle glaucoma.

          -  History of seizures.

          -  Use of MAO inhibitor drugs within the last 14 days.

          -  Abnormal baseline liver or renal function tests.

          -  Dementia or other syndrome of cognitive impairment that could interfere with the
             subject's ability to participate fully in the assessment protocol.

          -  Obstructive uropathy in males.
Clinical trial NCT00492856 (phase 3, status: completed)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: mercaptopurine, methotrexate, tretinoin
SMILES: S=C1N=CNC2=C1NC=N2, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Cytologically confirmed acute promyelocytic leukemia (APL) or the variant form of APL

               -  Previously untreated disease

               -  Low- or intermediate-risk disease

                    -  Low-risk disease, defined as white blood cell (WBC) ≤ 10,000/mm^3 and
                       platelet count > 40,000/mm^3

                    -  Intermediate-risk disease, defined as WBC ≤ 10,000/mm^3 and platelet count ≤
                       40,000/mm^3

                    -  WBC and platelet count confirming low- or intermediate-risk disease must be
                       obtained within 48 hours prior to study registration unless the patient
                       received tretinoin therapy prior to study registration in which case the WBC
                       and platelet count must be obtained within 48 hours prior to study therapy

          -  PML-RARα fusion gene positive by reverse transcriptase-polymerase chain reaction
             (RT-PCR) assay

          -  No recurrent disease

          -  Must be registered on clinical trials SWOG-9007 and SWOG-S9910

               -  Specimens must be collected prior to tretinoin therapy and may be collected after
                  tretinoin therapy

        PATIENT CHARACTERISTICS:

          -  Zubrod performance status 0-3

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception for ≥ 1 month prior to, during, and
             for 2 months after completion of study treatment

          -  No unstable cardiac arrhythmia or unstable angina

          -  No other malignancy within the past 5 years except for the following:

               -  Adequately treated basal cell or squamous cell skin cancer

               -  Carcinoma in situ of the cervix

               -  Adequately treated stage I or II cancer (except for highly aggressive
                  malignancies with a high rate of early relapse) currently in complete remission

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No more than 1 prior dose of intrathecal chemotherapy for acute leukemia

          -  No prior systemic chemotherapy, hydroxyurea, or leukapheresis for acute leukemia

               -  Prior tretinoin at a dose of ≤ 45 mg/m^2/day allowed provided it was received ≤ 5
                  days prior to study registration
Clinical trial NCT00686517 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: ribavirin
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with acute hepatitis C virus (HCV).

          -  Normal and Elevated serum alanine transferase (ALT) levels

          -  Positive serum HCV-RNA.

          -  Aged between 18 and 65 years.

          -  Negative urine or serum pregnancy test (for women of childbearing potential)
             documented within the 24-hour period prior to the first dose of the drug.
             Additionally, all fertile males with partners of childbearing age and females must be
             using reliable contraception during the study and additionally for participants
             treated with ribavirin, for 6 months (for woman) and 7 months (for man and his
             partner) after treatment completion

        Exclusion Criteria:

          -  Liver disease unrelated to HCV infection

          -  Hemoglobin (Hgb) <12g/dL in women and <13g/dL in men; white blood cells (WBC)
             <3,000/uL; platelets (PLTs) <100,000/ul

          -  Women with ongoing pregnancy or who are breast feeding

          -  History of severe psychiatric disease, especially depression

          -  History of neurologic disease, especially epilepsy

          -  History or evidence of symptoms of severe cardiac, gastrointestinal and kidney disease

          -  Positive anti-Human Immunodeficiency Virus (HIV) antibodies

          -  Positive anti-nuclear antibodies (ANA) and/or Anti-Smooth Muscle Antibody (ASMA)
             (>1/80)

          -  Positive Hepatitis B surface antigen (HBsAg)

          -  History of having received any systemic anti-neoplastic or immunomodulatory treatment
             in the previous 6 months

          -  History or other evidence of severe illness or any other conditions which would make
             the participants, in the opinion of investigator, unsuitable for the study (active
             drug addict except those under methadone treatment, thalassemic, dyalized included)
Clinical trial NCT00240331 (phase 3, status: completed)
Conditions: renal failure
ICD codes: P96.0, O03.32, O04.82, O08.4, O03.82, O07.32, I13.11
Drugs: 10mg rosuvastatin, placebo
SMILES: CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects with end-stage renal failure aged 50-80 years, who have
             received regular haemodialysis treatment for at least 3 months

        Exclusion Criteria:

          -  Subjects will have no underlying condition that is expected to limit survival to less
             than 1 year and is also unrelated to end-stage renal disease (ESRD). Subjects should
             not have received a statin therapy within the past 6 months
Clinical trial NCT01345630 (phase 3, status: terminated)
Conditions: hiv-1
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: maraviroc, emtricitabine/tenofovir, darunavir/ritonavir 800/100 mg, placebo for emtricitabine/tenofovir, placebo for maraviroc
SMILES: CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
Reason stopped: 
    see termination reason in detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Plasma HIV-1 RNA equal to or greater than 1,000 copies/mL measured at the Screening
             Visit.

          -  CD4 count equal to or greater than 100 cells/mm3 at Screening.

          -  Have only R5 HIV 1 at Screening as verified by a randomized tropism assay.

        Exclusion Criteria:

          -  Prior treatment with any other HIV antiretroviral therapy for more than 14 days at any
             time.

          -  Any evidence of genotypic/phenotypic resistance to darunavir, tenofovir, and
             emtricitabine.

          -  CXCR4 using virus detected using randomized tropism determination or repeated failure
             to obtain an interpretable tropism result.